Selank is a novel peptide anxiolytic drug. The name of the drug is an abbreviation of “selective anxiolytic”. It is used in Russia since 2009 for anxiety management.
Selank was developed at Zakusov Institute of Pharmacology, the same institute that developed Noopept, Afobazole, and Bromantane (Ladasten). By its structure, Selank is a derivative of Tuftsin, an endogenous peptide with immunostimulatory effect.
Besides pronounced anxiolytic action, the drug has nootropic, antidepressant, immunostimulant action and an excellent safety profile which is untypical for commonly used anxiety drugs.